Medical management of recurrent endometrioma with long-term norethindrone acetate
Ozgul Muneyyirci-Delale1,2, Jenny Anopa1, Cassandra Charles1, Deepali Mathur1, Rudolph Parris1, Jed B Cutler2, Ghadir Salame1,2, Ovadia Abulafia1,21Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, New York, NY, USA; 2Department of Obstetrics and Gynecology, Kings County Hospit...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-03-01
|
Series: | International Journal of Women's Health |
Online Access: | http://www.dovepress.com/medical-management-of-recurrent-endometrioma-with-long-term-norethindr-a9605 |
id |
doaj-53e0fe612f184a4d8fd777b686f11822 |
---|---|
record_format |
Article |
spelling |
doaj-53e0fe612f184a4d8fd777b686f118222020-11-24T22:23:04ZengDove Medical PressInternational Journal of Women's Health1179-14112012-03-012012default149154Medical management of recurrent endometrioma with long-term norethindrone acetateMuneyyirci-Delale OAnopa JCharles CMathur DParris RCutler JBSalame GAbulafia OOzgul Muneyyirci-Delale1,2, Jenny Anopa1, Cassandra Charles1, Deepali Mathur1, Rudolph Parris1, Jed B Cutler2, Ghadir Salame1,2, Ovadia Abulafia1,21Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, New York, NY, USA; 2Department of Obstetrics and Gynecology, Kings County Hospital Center, New York, NY, USAPurpose: Evaluate the efficacy of norethindrone acetate in the resolution of symptoms and regression of recurrent endometrioma.Patients and methods: Retrospective chart review at SUNY Downstate Medical Center of patients with a history of surgical excision of endometrioma (with histological confirmation) and recurrent endometrioma (demonstrated by strict sonographic criterion of endometrioma) who were willing to undergo follow-up. Patients were prescribed norethindrone acetate to be taken daily with follow-up sonograms until cysts regressed. Statistical analysis included Student's t-test and a simple linear regression model to assess cyst regression over time during treatment.Results: Degree of pain was significantly lower on treatment when compared to baseline (P < 0.00001). Cyst size was significantly smaller in as little as 3 months (P < 0.0001). Average rate of regression with continuous treatment was 0.025 ± 0.015 cm/day. Total mean ± standard deviation regression time is 10.28 ± 8.25 months.Conclusion: Norethindrone acetate was effective in eradicating symptoms and producing complete regression of recurrent endometriomas. It should be considered for patients who are likely to adhere to a prolonged treatment regimen and comply with recommendations for surveillance with serial sonograms.Keywords: endometriosis, regression, dysmenorrhea, medical therapyhttp://www.dovepress.com/medical-management-of-recurrent-endometrioma-with-long-term-norethindr-a9605 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Muneyyirci-Delale O Anopa J Charles C Mathur D Parris R Cutler JB Salame G Abulafia O |
spellingShingle |
Muneyyirci-Delale O Anopa J Charles C Mathur D Parris R Cutler JB Salame G Abulafia O Medical management of recurrent endometrioma with long-term norethindrone acetate International Journal of Women's Health |
author_facet |
Muneyyirci-Delale O Anopa J Charles C Mathur D Parris R Cutler JB Salame G Abulafia O |
author_sort |
Muneyyirci-Delale O |
title |
Medical management of recurrent endometrioma with long-term norethindrone acetate |
title_short |
Medical management of recurrent endometrioma with long-term norethindrone acetate |
title_full |
Medical management of recurrent endometrioma with long-term norethindrone acetate |
title_fullStr |
Medical management of recurrent endometrioma with long-term norethindrone acetate |
title_full_unstemmed |
Medical management of recurrent endometrioma with long-term norethindrone acetate |
title_sort |
medical management of recurrent endometrioma with long-term norethindrone acetate |
publisher |
Dove Medical Press |
series |
International Journal of Women's Health |
issn |
1179-1411 |
publishDate |
2012-03-01 |
description |
Ozgul Muneyyirci-Delale1,2, Jenny Anopa1, Cassandra Charles1, Deepali Mathur1, Rudolph Parris1, Jed B Cutler2, Ghadir Salame1,2, Ovadia Abulafia1,21Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, New York, NY, USA; 2Department of Obstetrics and Gynecology, Kings County Hospital Center, New York, NY, USAPurpose: Evaluate the efficacy of norethindrone acetate in the resolution of symptoms and regression of recurrent endometrioma.Patients and methods: Retrospective chart review at SUNY Downstate Medical Center of patients with a history of surgical excision of endometrioma (with histological confirmation) and recurrent endometrioma (demonstrated by strict sonographic criterion of endometrioma) who were willing to undergo follow-up. Patients were prescribed norethindrone acetate to be taken daily with follow-up sonograms until cysts regressed. Statistical analysis included Student's t-test and a simple linear regression model to assess cyst regression over time during treatment.Results: Degree of pain was significantly lower on treatment when compared to baseline (P < 0.00001). Cyst size was significantly smaller in as little as 3 months (P < 0.0001). Average rate of regression with continuous treatment was 0.025 ± 0.015 cm/day. Total mean ± standard deviation regression time is 10.28 ± 8.25 months.Conclusion: Norethindrone acetate was effective in eradicating symptoms and producing complete regression of recurrent endometriomas. It should be considered for patients who are likely to adhere to a prolonged treatment regimen and comply with recommendations for surveillance with serial sonograms.Keywords: endometriosis, regression, dysmenorrhea, medical therapy |
url |
http://www.dovepress.com/medical-management-of-recurrent-endometrioma-with-long-term-norethindr-a9605 |
work_keys_str_mv |
AT muneyyircidelaleo medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate AT anopaj medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate AT charlesc medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate AT mathurd medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate AT parrisr medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate AT cutlerjb medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate AT salameg medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate AT abulafiao medicalmanagementofrecurrentendometriomawithlongtermnorethindroneacetate |
_version_ |
1725766082790162432 |